Lack of over-expression of T cell receptor Vbeta5.2 in myelin basic protein-specific T cell lines derived from HLA-DR2 positive multiple sclerosis patients and controls.
Based on studies reporting an overexpression of certain V genes in myelin basic protein (MBP)-specific T cells from MS patients, immunotherapies targeting single TCR (Vbeta5.2, Vbeta6.1) are currently under way. In order to assess the basic assumption for one of these therapeutic strategies, i.e. the overexpression of Vbeta5.2 by MBP-specific T cells, we analyzed 100 MBP-specific T cell lines (TCL) for Vbeta5.2 expression. Only 4 out of 100 TCL expressed Vbeta5.2, and expression of this TCR gene is therefore not more frequent than expected from the normal peripheral blood distribution.
Afshar
G
G
Neuroimmunology Branch, NINDS, National Institutes of Health, Bethesda, MD 20892-1400, USA.
Muraro
P A
PA
McFarland
H F
HF
Martin
R
R
D000328:Adult; D000368:Aged; D005260:Female; D019674:Genes, T-Cell Receptor beta / Q000235:genetics*; D015802:HLA-DR2 Antigen / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D004676:Myelin Basic Protein / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism*; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism*
D015802:HLA-DR2 Antigen; D004676:Myelin Basic Protein; D012333:RNA, Messenger